GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Thyrocare Technologies Ltd

Thyrocare Technologies: API Holdings Amalgamation with Docon Technologies Sanctioned

M&A ● No Immediate Change LOW RISK
📅 Filed on BSE: 01 Sep 2026, 05:21 PM IST  ·  BSE ID: e9fa8b03-015a-497e-91ad-c0f15bb04211
View Original BSE Filing (PDF)
💡
In Simple Terms
A group company owning 51.02% of Thyrocare is merging into its parent, transferring its shares to the parent.
🤖 AI Summary
  • NCLT Mumbai Bench sanctioned the amalgamation of Docon Technologies Private Limited with API Holdings Limited on August 31, 2026.
  • Docon's 8,12,00,000 equity shares, representing 51.02% of Thyrocare's paid-up share capital, will transfer to API Holdings.
  • The scheme becomes operative upon the Effective Date, once NCLT Order is filed with the Registrar of Companies.
  • Docon is a wholly-owned subsidiary of API; both are currently part of Thyrocare's Promoter Group.
  • Aggregate Promoter Group shareholding in Thyrocare remains 51.02% post-amalgamation, held by API.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Shares held by Docon Technologies before Scheme
8,12,00,000 equity shares
% of holding by Docon Technologies before Scheme
51.02%
Shares held by API Holdings after Scheme
8,12,00,000 equity shares
% of holding by API Holdings after Scheme
51.02%
Total Public Shareholders %
48.98%
Total Paid-up Share Capital
15,91,65,315 shares
🏢 How This Affects the Company
⚠️
Risk Impact
This internal corporate restructuring within the promoter group introduces no new operational or financial risks for Thyrocare Technologies.
👥 What This Means For Shareholders
✅
Action Required
No action is required from existing public shareholders of Thyrocare Technologies Limited as a result of this internal promoter group restructuring.
👤
Who Is Affected
Public shareholders of Thyrocare Technologies are unaffected, as their 48.98% shareholding remains unchanged. The change is internal to the Promoter Group, with API Holdings taking over Docon Technologies' 51.02% stake.
🔍
Management Signal
The decision indicates management's intent to streamline the corporate structure within its promoter group by amalgamating Docon Technologies into API Holdings.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Filing of certified NCLT Order with the Registrar of Companies for effective date.
Company announcement of the 'Effective Date' for the amalgamation.
Next quarterly shareholding pattern to reflect the change from Docon to API.
LOW RISK This is an internal promoter group restructuring with no impact on Thyrocare's operations or public shareholding.
💡 Investor Takeaway
The NCLT sanctioned amalgamation of Docon Technologies Private Limited with API Holdings Limited means Docon’s 8,12,00,000 equity shares (51.02% of Thyrocare) will transfer to API. The aggregate Promoter Group holding remains 51.02%, with API holding it post-Effective Date.
⚖️ Strengths & Concerns

✅ Positives

  • No change in the aggregate shareholding of the Promoter and Promoter Group, remaining at 51.02% post-amalgamation.
  • The transaction simplifies the promoter group structure, consolidating Docon Technologies' stake into API Holdings.
❓ Frequently Asked Questions
What is the status of the amalgamation of Docon Technologies with API Holdings?
The Hon'ble NCLT, Mumbai Bench, sanctioned the Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited via an order pronounced on August 31, 2026.
How does the amalgamation affect Docon Technologies' shareholding in Thyrocare Technologies?
Upon the scheme becoming effective, Docon Technologies' entire shareholding in Thyrocare, comprising 8,12,00,000 equity shares representing 51.02% of the paid-up share capital, will transfer to API Holdings.
Will the amalgamation change the total Promoter Group shareholding in Thyrocare Technologies?
No, the amalgamation will not change the aggregate shareholding of the Promoter and Promoter Group of Thyrocare Technologies, which will continue to be 51.02%.
Who will hold the 51.02% promoter group shares in Thyrocare Technologies after the amalgamation?
Post the Effective Date of the amalgamation, API Holdings, being a member of the Promoter Group, will hold the 8,12,00,000 equity shares, representing 51.02% of Thyrocare's paid-up share capital.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.